Two novel cardiovascular PET agents are in the wings from FluoroPharma Medical, according to a recent profile in Forbes magazine.

Phase II clinical trials are already underway for the compounds and the company expects the BFPET (blood-flow PET) techniques to be made available for clinical use by 2016.